{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:08:02Z","timestamp":1779433682988,"version":"3.53.1"},"reference-count":39,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2026]]},"abstract":"<jats:p>Background: To explore the value of serum soluble CD40\nligand (sCD40L) and galectin-3 (galectin-3) for predicting\nthe therapeutic effect and prognosis of patients with acute\nischemic stroke (AIS).\nMethods: 180 AIS patients admitted to the hospital\nbetween March 2023 and March 2025 were selected as\nresearch participants. All patients received emergency\ntreatment with tenecteplase (TNK-tPA) combined with\nXuesaitong. Based on the therapeutic effect, patients were\ndivided into two groups: an effective group and an ineffective group. Serum sCD40L and galectin-3 levels were\nmeasured in both groups before treatment and 4 weeks\nafter, and the levels were compared. After discharge, all\npatients were monitored for 3 months, and, based on their\nmodified Rankin Scale (mRS) score, those with a good\nprognosis and those with a poor prognosis were assigned\nto two groups. Using multivariate logistic regression, the\nrisk factors associated with poor prognosis and inadequate\ntreatment in AIS patients were examined. Serum levels of\nsCD40L and galectin-3 were analysed using a receiver\noperating characteristic (ROC) curve to assess their prognostic value for poor prognosis and ineffective treatment in\nAIS patients.\nResults: Of the 180 research subjects, 146 were effectively\ntreated (effective group), while 34 were ineffective (ineffective group). There were 142 patients with a good prognosis\nand 38 with a poor prognosis, representing an incidence of\n21.11%. After 4 weeks of treatment, serum levels of\nsCD40L and galectin-3 were lower in the successful group than in the unsuccessful group (P&amp;lt; 0.05). Serum levels of\nsCD40L and galectin-3 were higher in the poor-prognosis\ngroup than in the favourable-prognosis group (P&amp;lt; 0.05).\nMultivariate logistic regression analysis showed that AIS\npatients with elevated serum galectin-3 and sCD40L levels\nwere at increased risk of inadequate treatment and poor\noutcomes (P&amp;lt; 0.05). The areas under the curve (AUCs) for\nserum galectin-3 and sCD40L in predicting treatment failure in AIS patients were 0.665 and 0.691, respectively,\naccording to ROC analysis; the specificities were 70.08%\nand 77.51% , respectively, and the sensitivities were 62.53%\nand 62.58%, respectively. The combined prediction model\nfor ineffective treatment using serum galectin-3 and\nsCD40L yielded an AUC of 0.784, with specificities and\nsensitivities of 65.18% and 81.25%, respectively. For predicting poor prognosis, serum galectin-3 and scd40l\ndemonstrated AUCs of 0.774 and 0.838, respectively; their\nspecificities were 67.58% and 75.36% , respectively, while\ntheir sensitivities were 75.06% and 80.04% , respectively.\nThe combined prediction of serum galectin-3 and scd40l\nfor poor prognosis was less effective, with an AUC of 0.919,\na specificity of 60.05%, and a sensitivity of 90.63%.\nConclusions: Both sCD40L and serum galectin-3 levels\nhave some prognostic value for poor prognosis and ineffective treatment in AIS patients, and combining their detection can significantly improve predictive efficacy.<\/jats:p>","DOI":"10.5937\/jomb0-61699","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T08:45:01Z","timestamp":1763455501000},"page":"1163-1173","source":"Crossref","is-referenced-by-count":0,"title":["Serum sCD40L and galectin-3 in the prognosis prediction of patients with acute ischemic stroke"],"prefix":"10.5937","volume":"45","author":[{"given":"Zhiqin","family":"Chen","sequence":"first","affiliation":[{"name":"Nanchang University, Jiangxi Medical College, The Second Affiliated Hospital, Department of Neurosurgery, Nanchang City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanhua","family":"Xiao","sequence":"additional","affiliation":[{"name":"Nanchang University, Jiangxi Medical College, The Second Affiliated Hospital, Department of Neurosurgery, Nanchang City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunqing","family":"Luo","sequence":"additional","affiliation":[{"name":"Nanchang University, Jiangxi Medical College, The Second Affiliated Hospital, Department of Neurosurgery, Nanchang City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shuping","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University, Neurology Department, Jinan City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhaoyang","sequence":"additional","affiliation":[{"name":"Qilu Hospital of Shandong University, Neurology Department, Jinan City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Lai","sequence":"additional","affiliation":[{"name":"Nanchang University, Jiangxi Medical College, The Second Affiliated Hospital, Department of Neurosurgery, Nanchang City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"#cr-split#-ref1.1","doi-asserted-by":"crossref","unstructured":"Palaiodimou L, Katsanos AH, Turc G, Asimakopoulos AG, Mavridis D, Schellinger PD, Theodorou A, Lemmens R, Sacco S, Safouris A, Katan M, Sarraj A, Fischer U, Tsivgoulis G. Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomised Trials. Neurology 2024 Nov 12","DOI":"10.1212\/WNL.0000000000209903"},{"key":"#cr-split#-ref1.2","doi-asserted-by":"crossref","unstructured":"103(9): e209903. doi: 10.1212\/WNL.0000000000209903. Epub 2024 Oct 16. PMID: 39413337;","DOI":"10.1212\/WNL.0000000000209903"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Abuelazm M, Seri AR, Awad AK, Ahmad U, Mahmoud A, Albazee E, Kambalapalli S, Abdelazeem B. The efficacy and safety of tenecteplase versus alteplase for acute ischemic stroke: an updated systematic review, pairwise, and network meta-analysis of randomised controlled trials. J Thromb Thrombolysis 2023 Feb; 55(2): 322-38. doi: 10.1007\/s11239-022-02730-5. Epub 2022 Nov 30. PMID: 36449231; PMCID: PMC10011306;","DOI":"10.1007\/s11239-022-02730-5"},{"key":"#cr-split#-ref3.1","doi-asserted-by":"crossref","unstructured":"Wang Y, Cai X, Fang Q, Zhu J. Efficacy and safety outcomes of Tenecteplase versus Alteplase for thrombolysis of acute ischemic stroke: A meta-analysis of 9 randomised controlled trials. J Neurol Sci 2024 Mar 15","DOI":"10.1016\/j.jns.2024.122912"},{"key":"#cr-split#-ref3.2","doi-asserted-by":"crossref","unstructured":"458: 122912. doi: 10.1016\/j.jns.2024.122912. Epub 2024 Feb 3. PMID: 38325064;","DOI":"10.1016\/j.jns.2024.122912"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Zhou Y, He Y, Campbell BCV, Liebeskind DS, Yuan C, Chen H, Zhang Y, Yi T, Luo Z, Zhang Z, Meng C, Cheng J, Ouyang H, Hu J, Wang F, Zhang S, Fang Q, Hu H, Zhang X, Chen Y, Zhong W, Lansberg MG, Yan S, Lou M; HOPE investigators. Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. JAMA 2025 Sep 2; 334(9): 788-97. doi: 10.1001\/jama.2025.12063. PMID: 40773205; PMCID: PMC12332759;","DOI":"10.1001\/jama.2025.12063"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Anjos JM, Neto MG, de Araujo Tapparelli Y, Tse G, Biondi-Zoccai G, de Souza Lima Bitar Y, Roever L, Duraes AR. Efficacy and safety of very early mobilisation after thrombolysis in acute ischemic stroke: a randomised clinical trial. J Neurol 2023 Feb; 270(2): 843-50. doi: 10.1007\/s00415-022-11411-5. Epub 2022 Oct 11. PMID: 36219243; PMCID: PMC9552146;","DOI":"10.1007\/s00415-022-11411-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Houkin K, Osanai T, Uchiyama S, Minematsu K, Taguchi A, Maruichi K, Niiya Y, Asaoka K, Kuga Y, Takizawa K, Haraguchi K, Yashimura S, Kimura K, Tokunaga K, Aoyama A, Ikawa F, Inenaga C, Abe T, Tominaga A, Takahashi S, Kudo K, Fujimura M, Sugiyama T, Ito M, Kawabori M, Hess DC, Savitz SI, Hirano T; TREASURE Study Investigators. Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2\/3 TREASURE Randomised Clinical Trial. JAMA Neurol 2024 Feb 1; 81(2): 154-62. doi: 10.1001\/jamaneurol.2023.5200. PMID: 38227308; PMCID: PMC10792497;","DOI":"10.1001\/jamaneurol.2023.5200"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Claren\u00e7on F, Durand-Zaleski I, Premat K, Baptiste A, Chabert E, Ferrier A, Labeyrie MA, Reiner P, Spelle L, Denier C, Tuilier T, Hosseini H, Rodriguez-R\u00e9gent C, Turc G, Fauch\u00e9 C, Lamy M, Lapergue B, Consoli A, Barbier C, Boulanger M, Bricout N, Henon H, Gory B, Richard S, Rouchaud A, Macian-Montoro F, Eker O, Cho TH, Soize S, Moulin S, Gentric JC, Timsit S, Darcourt J, Albucher JF, Janot K, Annan M, Pico F, Costalat V, Arquizan C, Marnat G, Sibon I, Pop R, Wolff V, Shotar E, Lenck S, Sourour NA, Radenne A, Alamowitch S, Dechartres A. Evaluation of mechanical thrombectomy in acute ischemic stroke related to a distal arterial occlusion: A randomised controlled trial. Int J Stroke 2024 Mar; 19(3): 367-72. doi: 10.1177\/17474930231205213. Epub 2023 Oct 12. PMID: 37740419;","DOI":"10.1177\/17474930231205213"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ghannam M, AlMajali M, Galecio-Castillo M, Al Qudah A, Khasiyev F, Dibas M, Ghazaleh D, Vivanco-Suarez J, Moran-Marinos C, Farooqui M, Rodriguez-Calienes A, Koul P, Roeder H, Shim H, Samaniego E, Leira EC, Adams HP Jr, Ortega-Gutierrez S. Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2023 Dec 19; 12(24): e031669. doi: 10.1161\/JAHA.123.031669. Epub 2023 Dec 18. PMID: 38108256; PMCID: PMC10863770;","DOI":"10.1161\/JAHA.123.031669"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Rose D, Cavalier A, Kam W, Cantrell S, Lusk J, Schrag M, Yaghi S, Stretz C, de Havenon A, Saldanha IJ, Wu TY, Ranta A, Barber PA, Marriott E, Feng W, Kosinski AS, Laskowitz D, Poli S, Mac Grory B. Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke 2023 May; 54(5): 1192-204. doi: 10.1161\/STROKEAHA.122.042335. Epub 2023 Mar 23. PMID: 36951049; PMCID: PMC10133185;","DOI":"10.1161\/STROKEAHA.122.042335"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kan X, Yan Z, Wang F, Tao X, Xue T, Chen Z, Wang Z, Chen G. Efficacy and safety of remote ischemic conditioning for acute ischemic stroke: A comprehensive meta-analysis from randomised controlled trials. CNS Neurosci Ther 2023 Sep; 29(9): 2445-56. doi: 10.1111\/cns.14240. Epub 2023 May 14. PMID: 37183341; PMCID: PMC10401132;","DOI":"10.1111\/cns.14240"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu H, Jin A, Pan Y, Meng X, Li H, Li Z, Wang Y, Li S. Efficacy and Safety of Intravenous Tenecteplase Versus Alteplase in Treating Acute Ischemic Stroke With Diabetes and Admission Hyperglycemia. J Am Heart Assoc 2024 Oct 15; 13(20): e036393. doi: 10.1161\/JAHA.124.036393. Epub 2024 Oct 11. PMID: 39392168; PMCID: PMC11935594;","DOI":"10.1161\/JAHA.124.036393"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV\/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY) 2021 Apr 20; 13(8): 10833-52. doi: 10.18632\/aging.202860. Epub 2021 Apr 20. PMID: 33879634; PMCID: PMC8109137;","DOI":"10.18632\/aging.202860"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Sadeghi-Hokmabadi E, Mirzaei F, Yazdchi M, Jalili J, Sadeghpour Y, Nemati-Anari B, Farhoudi M, Hamian Roumiani P. Efficacy and safety of decompressive craniectomy in acute ischemic stroke patients treated with intravenous thrombolysis. BMC Neurol 2023 Mar 28; 23(1): 125. doi: 10.1186\/s12883-022-03014-4. PMID: 36978002; PMCID: PMC10045929;","DOI":"10.1186\/s12883-022-03014-4"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Qiu Z, Li F, Xie D, Yuan G, Nguyen TN, Zhou K, Nogueira RG, Saver JL, Campbell BCV, Albers GW, Sang H, Li L, Tian Y, Meng Z, Wang D, Zi W, Yang Q; BRIDGE-TNK investigators. Efficacy and Safety of Intravenous Tenecteplase Before Endovascular Thrombectomy for Acute Ischemic Stroke: The Multicenter, Randomized, BRIDGE-TNK Trial Protocol. J Am Heart Assoc 2024 Nov 5; 13(21): e036765. doi: 10.1161\/JAHA.124.036765. Epub 2024 Oct 22. PMID: 39435713; PMCID: PMC11935713;","DOI":"10.1161\/JAHA.124.036765"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Xu S, Zhang W, Zhang Y, Xu Z, Wu T. Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration. Discov Med 2023 Apr 1; 35(175): 185-92. doi: 10.24976\/Discov.Med.202335175.19. PMID: 37105928;","DOI":"10.24976\/Discov.Med.202335175.19"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Liu S, Wang S, Zou Q, Pu Y, Li X, Hang Z, Cai Z, Wang C. Efficacy and safety of batroxobin in patients with acute ischemic stroke: A multicenter retrospective analysis. CNS Neurosci Ther 2024 Aug; 30(8): e14877. doi: 10.1111\/cns.14877. PMID: 39097914; PMCID: PMC11298195;","DOI":"10.1111\/cns.14877"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines 2022 Sep 10; 10(9): 2248. doi: 10.3390\/biomedicines10092248. PMID: 36140350; PMCID: PMC9496572;","DOI":"10.3390\/biomedicines10092248"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Shi H, Hou MM, Ren G, He ZF, Liu XL, Li XY, Sun B. Tirofiban for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis: A Systematic Review and Meta-Analysis. Cerebrovasc Dis 2023; 52(5): 587-96. doi: 10.1159\/000527861. Epub 2022 Dec 29. PMID: 36580906;","DOI":"10.1159\/000527861"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Wang R, Zhang Y, Shao Y, Yang X, Chen L. Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke: A Retrospective Single-Center Study. Neurologist 2024 Jan 1; 29(1): 36-40. doi: 10.1097\/NRL.0000000000000518. PMID: 37582684;","DOI":"10.1097\/NRL.0000000000000518"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines 2023 Jun 29; 11(7): 1861. doi: 10.3390\/biomedicines11071861. PMID: 37509501; PMCID: PMC10377220;","DOI":"10.3390\/biomedicines11071861"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Huang H, Zhang J, Lin J, Shi S. Efficacy and safety of mesenchymal stem cells in patients with acute ischemic stroke: a meta-analysis. BMC Neurol 2024 Jan 29; 24(1): 48. doi: 10.1186\/s12883-024-03542-1. PMID: 38287288; PMCID: PMC10823675;","DOI":"10.1186\/s12883-024-03542-1"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Liang H, Wang X, Quan X, Qin B, Zhang J, Liang S, Liang Z. Safety and efficacy of intravenous thrombolysis in patients with acute ischemic stroke taking direct oral anticoagulants prior to stroke: a meta-analysis. J Neurol 2023 Sep; 270(9): 4192-200. doi: 10.1007\/s00415-023-11815-x. Epub 2023 Jun 14. PMID: 37314507;","DOI":"10.1007\/s00415-023-11815-x"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs 2022 Jan 1; 33(1): e590-e603. doi: 10.1097\/CAD.0000000000001189. PMID: 3438240; PMCID: PMC8670349;","DOI":"10.1097\/CAD.0000000000001189"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Medina-Rodr\u00edguez M, Moniche F, de Alboniga-Chindurza A, Ortega-Quintanilla J, Ainz-Gomez L, Pardo-Galiana B, Cabezas-Rodriguez JA, Aguilar-P\u00e9rez M, Zamora A, Delgado-Acosta F, Jim\u00e9nez-Gomez E, Bravo Rey I, Oteros Fernandez R, Freijo Guerrero MDM, Gonzalez Diaz E, Escudero-Martinez I, Morales Caba L, Vielba-Gomez I, Mosteiro S, Castellanos Rodrigo MDM, Amaya Pascasio L, Hidalgo C, Fernandez Prudencio L, Ramirez Moreno JM, Diaz P\u00e9rez J, Sanz-Fernandez G, Baena-Palomino P, Gamero-Garcia MA, Jim\u00e9nez Jorge S, Rosso Fernandez C, Montaner J, Gonzalez Garcia A, Zapata-Arriaza E. Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomised clinical trial (ATILA) protocol. Eur Stroke J 2023 Mar; 8(1): 380-6. doi: 10.1177\/23969873221146383. Epub 2022 Dec 28. PMID: 37021200; PMCID: PMC10069213;","DOI":"10.1177\/23969873221146383"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting 2024; 10(1): 1256. doi: 10.36922\/ijb.1256;","DOI":"10.36922\/ijb.1256"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Liu C, Yang X, Liu M, Wang J, Li G. Systematic review and meta-analysis of the efficacy and safety of adjunctive use of tirofiban in patients treated with endovascular therapy for acute ischemic stroke at different embolic sites. Medicine (Baltimore) 2023 Oct 6; 102(40): e35091. doi: 10.1097\/MD.00000000000035091. PMID: 37800797; PMCID: PMC10553052;","DOI":"10.1097\/MD.0000000000035091"},{"key":"#cr-split#-ref27.1","doi-asserted-by":"crossref","unstructured":"Zheng X, Cheng S, Gao Y, Lai X. Efficacy and safety of traditional Chinese medicine for acute ischemic stroke by resolving phlegm and unblocking fu-organs: A systematic review and meta-analysis. J Ethnopharmacol 2024 Apr 6","DOI":"10.1016\/j.jep.2023.117660"},{"key":"#cr-split#-ref27.2","doi-asserted-by":"crossref","unstructured":"323: 117660. doi: 10.1016\/j.jep.2023.117660. Epub 2023 Dec 29. PMID: 38160868;","DOI":"10.1016\/j.jep.2023.117660"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Yan X, Wang B, Xia P, Lan C, Wang Q, Ge W, Zhou Y, Jiang C. Efficacy and Safety of Anticoagulant Therapy Versus Antiplatelet Therapy in Acute Ischemic Stroke Patients with Atrial Fibrillation. Clin Appl Thromb Hemost 2023 Jan-Dec; 29: 10760296231213070. doi: 10.1177\/10760296231213070. PMID: 37956462; PMCID: PMC10644758;","DOI":"10.1177\/10760296231213070"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Liu W, Zhao J, Liu H, Li T, Zhou T, He Y, Zhu L, Ding Y, Hui FK, He Y. Safety and Efficacy of Direct Thrombectomy Versus Bridging Therapy in Patients with Acute Ischemic Stroke Eligible for Intravenous Thrombolysis: A Meta-Analysis of Randomized Controlled Trials. World Neurosurg 2023 Jul; 175: 113-21.e3. doi: 10.1016\/j.wneu.2023.04.018. Epub 2023 Apr 10. PMID: 37040841;","DOI":"10.1016\/j.wneu.2023.04.018"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel) 2024 Feb 12; 12(2): 186. doi: 10.3390\/vaccines12020186. PMID: 38400169; PMCID: PMC10891594;","DOI":"10.3390\/vaccines12020186"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Garayzade R, Berlis A, Schiele S, Ertl M, Schneider H, M\u00fcller G, Maurer CJ. Efficacy and Safety Outcomes for Acute Ischemic Stroke Patients Treated with Intravenous Infusion of Tirofiban After Emergent Carotid Artery Stenting. Clin Neuroradiol 2024 Mar; 34(1): 163-72. doi: 10.1007\/s00062-023-01350-7. Epub 2023 Oct 5. PMID: 37796321; PMCID: PMC10881598;","DOI":"10.1007\/s00062-023-01350-7"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Clottes P, Bochaton T, Mechtouff L, Derex L, Cho TH, Fontaine J, Rascle L, Berthez\u00e8ne Y, Amaz C, Thibault H, Bergerot C, Nighoghossian N, Ong E. Safety and efficacy of reperfusion therapies in acute ischemic stroke related to left ventricular thrombus: A retrospective cohort study. Rev Neurol (Paris) 2024 Sep; 180(7): 608-14. doi: 10.1016\/j.neurol.2023.12.009. Epub 2024 Mar 1. PMID: 38431497;","DOI":"10.1016\/j.neurol.2023.12.009"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon 2024 Mar 28; 10(7): e28282. doi: 10.1016\/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709;","DOI":"10.1016\/j.heliyon.2024.e28282"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Srisurapanont K, Uawithya E, Dhanasomboon P, Pollasen N, Thiankhaw K. Comparative efficacy and safety among different doses of tenecteplase for acute ischemic stroke: A systematic review and network meta-analysis. J Stroke Cerebrovasc Dis 2024 Aug; 33(8): 107822. doi: 10.1016\/j.jstrokecerebrovasdis.2024.107822. Epub 2024 Jun 17. PMID: 38897370;","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107822"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Monteiro GA, Mutarelli A, Leite M, Marinheiro G, Araujo B, Gon\u00e7alves OR, Cavalcante-Neto JF, Leal PRL, da Ponte KF, Figueiredo EG, Telles JPM. Efficacy and safety of intravenous tirofiban versus standard medical treatment in acute ischemic stroke: A meta-analysis of randomised controlled trials. Clin Neurol Neurosurg 2024 Dec; 247: 108602. doi: 10.1016\/j.clineuro.2024.108602. Epub 2024 Oct 25. PMID: 39499994;","DOI":"10.1016\/j.clineuro.2024.108602"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Aref HM, El-Khawas H, Elbassiouny A, Shokri HM, Zeinhom MG, Roushdy TM. A randomised pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke. Neurol Sci 2023 Feb; 44(2): 765-71. doi: 10.1007\/s10072-022-06525-7. Epub 2022 Nov 30. PMID: 36446950; PMCID: PMC9842543;","DOI":"10.1007\/s10072-022-06525-7"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Serumski sCD40L i galektin-3 pri predvi\u0111anju prognoze kod pacijenata sa akutnim ishemijskim mo\u017edanim udarom"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/61699\/29323","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2026\/1452-82582605163C.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:40:28Z","timestamp":1779432028000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582605163C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-61699","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}